← Back to headlines
AbbVie Lowers Q1 and FY 2026 Earnings Outlook After R&D Charge
AbbVie has revised down its earnings outlook for the first quarter and full fiscal year 2026, following a significant $744 million research and development charge.
6 Apr, 11:18 — 6 Apr, 11:18
Sources
Showing 1 of 1 sources
Related Stories
US-Iran Military Escalation Sparks Retaliatory Strikes and Market Volatility
26m ago
BP Appoints Ian Tyler as New Chairman Following Leadership Transition
32m ago
Everus Construction and California Resources Finalize Major Corporate Acquisitions
51m ago
Nvidia Nears $14 Billion Acquisition of AI Startup Hugging Face
1h ago